NMR structure of an anti-gp120 antibody complex with a V3 peptide reveals a surface important for co-receptor binding

Structure

Volumn 8, Issue 4, 2000, Pages 385-395

  Tugarinov, Vitali ^a   Zvi, Anat ^a   Levy, Rina ^a   Hayek, Yehezkiel ^a   Matsushita, Shuzo ^b   Anglister, Jacob ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

Anti gp120 antibody; Co receptor; HIV 1; NMR; V3 loop

Indexed keywords

CHEMOKINE RECEPTOR; ENVELOPE PROTEIN; GLYCOPROTEIN GP 120; VIRUS GLYCOPROTEIN;

ARTICLE; BINDING SITE; CARBON NUCLEAR MAGNETIC RESONANCE; CRYSTAL STRUCTURE; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RECEPTOR BINDING; VIRUS CELL INTERACTION; VIRUS GENOME;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0034656348     PISSN: 09692126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-2126(00)00119-2     Document Type: Article

References (71)

1. Berger E.A., Sodroski J.et al. A new classification for HIV-1. Nature. 391:1998;240.
2. Alkhatib G., Berger E.A.et al. CC CKR5: a RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science. 272:1996;1955-1958.
3. Choe H., Sodrosky J.et al. The β-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell. 85:1996;1135-1148.
4. Deng H., Landau N.R.et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature. 381:1996;661-666.
5. Doranz B.J., Doms R.W.et al. A dual-tropic primary HIV-1 isolate that uses fusin and the β-chemokine receptors CKR-5, CKR-3 and CKR-2b as fusion cofactors. Cell. 85:1996;1149-1158.
6. Dragic T., Paxton W.A.et al. HIV-1 entry into CD4 cells is mediated by the chemokine receptor CC-CKR-5. Nature. 381:1996;667-673.
7. Feng Y., Broder C.C., Kennedy P.E., Berger E.A. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science. 272:1996;872-877.
8. Rusche J.R., Matthews T.J.et al. Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120. Proc. Natl Acad. Sci. USA. 85:1988;3198-3202.
9. Wu L., Sodroski J.et al. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature. 384:1996;179-183.
10. Trkola A., Moore J.P.et al. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature. 384:1996;184-187.
11. Cocchi F., Lusso P. The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine mediated blockade of infection. Nat. Med. 2:1996;1244-1247.
12. Rabehi L., Seddiki N., Benjouad A., Gluckman J.C., Gattegno L. Interaction of human immunodeficiency virus type 1 envelope glycoprotein V3 loop with CCR5 and CD4 at the membrane of human primary macrophages. AIDS Res. Hum. Retroviruses. 14:1998;1605-1615.
13. Xiao X., Dimitrov D.S.et al. Constitutive cell surface association between CD4 and CCR5. Proc. Natl Acad. Sci. USA. 96:1999;7496-7501.
14. Sakaida H., Uchiyama T.et al. T-tropic human immuno-deficiency virus type 1 (HIV-1)-derived V3 loop peptides directly bind to CXCR-4 and inhibit T-tropic HIV-1 infection. J. Virol. 72:1998;9763-9770.
15. Verrier F., Borman A.M., Brand D., Girard M. Role of the HIV type 1 glycoprotein 120 V3 loop in determining co-receptor usage. AIDS Res. Hum. Retroviruses. 15:1999;731-743.
16. Rizzuto C.D., Sodroski J.et al. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science. 280:1998;1949-1953.
17. Matthews T.J. Tenth anniversary perspectives on AIDS. AIDS Res. Hum. Retroviruses. 10:1994;631-632.
18. Moore J.P., Ho D.D.et al. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J. Virol. 69:1995;101-109.
19. VanCott T.C., Polonis V.R., Loomis L.D., Michael N.L., Nara P.L., Birx D.L. Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1. AIDS Res. Hum. Retroviruses. 11:1995;1379-1391.
20. Rini J.M., Stanfield R.L., Stura E.A., Salinas P.A., Profy A.T., Wilson I.A. Crystal structure of a human immunodeficiency virus type 1 neutralizing antibody, 50.1, in complex with its V3 loop peptide antigen. Proc. Natl Acad. Sci. USA. 90:1993;6325-6329.
21. Ghiara J.B., Stura E.A., Stanfield R.L., Profy A.T., Wilson I.A. Crystal structure of the principal neutralization site of HIV-1. Science. 264:1994;82-85.
22. Stanfield R.L., Cabezas E., Satterthwait A., Stura E., Profy A., Wilson I. Dual conformations for the HIV-1 gp120 V3 loop in complexes with different neutralizing Fabs. Structure. 7:1999;131-142.
23. Kwong P.D., Wyatt R., Robinson J., Sweet R.W., Sodroski J., Hendrickson W.A. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature. 393:1998;648-659.
24. Matsushita S., Putney S.et al. Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope. J. Virol. 62:1988;2107-2114.
25. Skinner M.A., Matthews T.J.et al. Characteristics of a neutralizing monoclonal antibody to the HIV envelope glycoprotein. Aids Res. Hum. Retroviruses. 4:1988;187-197.
26. IIIB: a two-dimensional NMR study. Biochemistry. 31:1992;6972-6979.
27. Zvi A., Anglister J.et al. Mapping of the antigenic determinant recognized by an anti-gp120 HIV neutralizing antibody by two-dimensional NMR. Eur. J. Biochem. 229:1995;178-187.
28. Zvi A., Feigelson D.J., Hayek Y., Anglister J. The conformation of the principal neutralizing determinant of HIV-1 in complex with an anti-gp120 HIV-neutralizing antibody studied by 2D-NMR difference spectroscopy. Biochemistry. 36:1997;8619-8627.
29. IIIB V3 peptide. Nat. Struct. Biol. 6:1999;331-335.
30. Zvi A., Tugarinov V., Faiman G.A., Horovitz A., Anglister J. A model of a gp120 V3 peptide in complex with an HIV-neutralizing antibody based on NMR and mutant cycle constraints. Eur. J. Biochem. 267:2000;767-779.
31. Chothia C., Lesk A.M. Canonical structures for the hypervariable regions of immunoglobulins. J. Mol. Biol. 19:1987;901-917.
32. Chothia C., Poljak R.J.et al. Conformations of immunoglobulin hypervariable regions. Nature. 342:1989;877-883.
33. Givol D. The minimal antigen binding fragment of antibodies-the Fv fragment. Mol. Immunol. 28:1991;1367-1379.
34. β assignments of the anti-gp120 antibody Fv fragment complexed with an antigenic peptide. J. Biomol. NMR. 13:1999;193-194.
35. 2 relaxation by mutual cancellation of dipole-dipole coupling and chemical shift anisotropy indicates an avenue to NMR structures of very large biological macromolecules. Proc. Natl Acad. Sci. USA. 94:1997;12366-12371.
36. 13C-labeled proteins. J. Am. Chem. Soc. 120:1998;6394-6400.
37. 13C-labeled proteins via scalar couplings. J. Am. Chem. Soc. 115:1993;11054-11055.
38. Sheriff S., Davies D.R.et al. Three-dimensional structure of an antibody-antigen complex. Proc. Natl Acad. Sci. USA. 84:1987;8075-8079.
39. Garbow J.R., Weitekamp D.P., Pines A. BIRD-bilinear rotation decoupling. Chem. Phys. Lett. 93:1982;514-518.
40. LaRosa G.J., Putney S.D. Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant. Science. 249:1990;932-935.
41. Morea V., Tramontano A., Rustici M., Chothia C., Lesk A.M. Conformations of the third hypervariable region in the VH domain of immunoglobulins. J. Mol. Biol. 275:1998;269-294.
42. Weliky D.P, Bennett A.E., Zvi A., Anglister J., Steinbach P.J., Tycko R. Solid-state NMR evidence for an antibody-dependent conformation of the V3 loop of HIV-1 gp120. Nat. Struct. Biol. 6:1999;141-145.
43. De Jong J-J., De Ronde A., Keulen W., Tersmette M., Goudsmit J. Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J. Virol. 66:1992;6777-6780.
44. Wang W-K., Dudek T., Essex M., Lee T-H. Hypervariable region 3 residues of HIV type 1 gp120 involved in CCR5 coreceptor utilization: therapeutic and prophylactic implications. Proc. Natl Acad. Sci. USA. 96:1999;4558-4562.
45. Faiman G., Levy R., Anglister J., Horovitz A. Contribution of arginine residues in the RP135 derived from the V3 loop of gp120 to its interaction with the Fv fragment of the 0.5β HIV-1 neutralizing antibody. J. Biol. Chem. 271:1996;13829-13833.
46. Delaglio F., Grzesiek S., Vuister G.W., Zhu G., Pfeifer J., Bax A. NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J. Biomol. NMR. 6:1995;277-293.
47. Johnson B.A., Blevins R.A. NMRView: a computer program for the visualization and analysis of NMR data. J. Biomol. NMR. 4:1994;603-614.
48. 15N enriched proteins. J. Biomol. NMR. 3:1993;185-204.
49. 13C magnetization. J. Magn. Reson. Series B. 101:1993;114-119.
50. 13C. J. Magn. Reson. Series B. 102:1993;103-106.
51. 13C-labeled proteins. J. Magn. Reson. 87:1990;620-627.
52. 13C-enriched proteins. J. Magn. Reson. 88:1990;425-431.
53. 13C-labeled proteins. J. Magn. Reson. Series B. 101:1993;110-113.
54. 2O. J. Am. Chem. Soc. 115:1993;2055-2057.
55. 15N-labeled proteins. J. Am. Chem. Soc. 111:1989;1515-1517.
56. Grzesiek S., Bax A. The importance of not saturating water in protein NMR. Application to sensitivity enhancement and NOE measurements. J. Am. Chem. Soc. 115:1993;12593-12594.
57. Lippens G., Dhalluin C., Wieruszeski J.M. Use of a water flip-back pulse in homonuclear NOESY. J. Biomol. NMR. 5:1995;327-331.
58. Zhu G., Kong X., Sze K. Gradient-enhanced TROSY NOE spectroscopy. J. Biomol. NMR. 13:1999;77-81.
59. 13C-labeled protein. J. Magn. Reson. 86:1990;204-209.
60. 13C-labeled proteins for the NMR assignment and structure determination of larger molecules. J. Magn. Reson. 86:1990;21-216.
61. Clore G.M., Gronenborn A.M. Structures of larger proteins in solution:three- and four-dimensional heteronuclear NMR spectroscopy. Science. 252:1991;1390-1999.
62. Bodenhausen G., Ruben D.J. Natural abundance nitrogen-15 NMR by enhanced heteronuclear spectroscopy. Chem. Phys. Lett. 69:1980;185-188.
63. Bax A., Vuister G.W.et al. Measurement of homo- and heteronuclear J-couplings from quantitative J-correlation. Methods Enzymol. 239:1994;79-105.
64. α J-couplings in calcium-free calmodulin using new 2D and 3D water-flip-back methods. J. Biomol. NMR. 4:1994;871-878.
65. β J-couplings in isotopically labeled proteins. J. Am. Chem. Soc. 117:1995;5312-5315.
66. NCγ couplings. J. Am. Chem. Soc. 119:1997;1803-1804.
67. Vuister G.W., Wang A.C., Bax A. Measurement of three-bond nitrogen-carbon J couplings in proteins uniformly enriched in nitrogen-15 and carbon-13. J. Am. Chem. Soc. 115:1993;5334-5335.
68. Brünger A.T. XPLOR Version 3.1. A System for X-ray Crystallography and NMR. 1993;Yale University Press, New Haven, CT.
69. Laskowsky R.A., Rullman J.A.C., MacArthur M.W., Kaptein R., Thornton J.M. AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR. J. Biomol. NMR. 8:1996;477-486.
70. Koradi R., Billeter M., Wüthrich K. MOLMOL: a program for display and analysis of macromolecular structures. J. Mol. Graphics. 14:1996;51-55.
71. Al-Lazikani B., Lesk A.M., Chothia C. Standard conformations for the canonical structures of immunoglobulins. J. Mol. Biol. 273:1997;927-948.